ERBB2 and breast carcinoma: In the ASTRRA study,4, 16 1282 patients with premenopausal HR+ breast cancer who received chemotherapy were enrolled, including 176 (13.7%) HR+/HER2+ premenopausal breast cancer patients with unknown trastuzumab treatment status.